Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Theravance Biopharma, Inc.NASDAQ: TBPH

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities remains negative

Q1 FY2026 other current liabilities was $5.91M, compared with $0 a year earlier.

Context

  • Other current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.91M-14.5% QoQ
Last fiscal yearDec 2025
$6.91M— YoY
Year agoMar 2025
$0— since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
6.91M USD
Year-over-year change
—
4-year CAGR
-27.6%

Other Current Liabilities vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Other current liabilities amounts to 1.3% of total assets for TBPH, versus a peer median of 3.9%.
TBPH Competitors
Other Current Liabilities for TBPH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VALNValneva SEMar 2026€50.99M EUR+68.8%-39.5%13.7%
VIRVir Biotechnology, Inc.Mar 2026$50.13M USD+186.4%+113.3%4.9%
GERNGeron CorporationMar 2026$30.97M USD+23.2%+91.4%5.8%
REPLReplimune Group, Inc.Dec 2025$15.69M USD-17.9%-4.1%4.7%
TYRATyra Biosciences, Inc.Mar 2026$13.11M USD——3.2%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$6.28M USD-24.0%+2.8%0.9%
TBPHTheravance Biopharma, Inc.Mar 2026$5.91M USD——1.3%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$1.93M USD+24.3%—0.6%
LENZLENZ Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding TBPH) —+23.7%+2.8%3.9%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents89.96M298.17M39.55M37.8M167.81M
Short-term Investments83.51M29.31M62.88M50.55M147.55M
Net Receivables57.6M16.79M17.47M68.44M95.54M
Inventory00000
Other Current Assets8.56M7.68M11.6M4.2M7.56M
Total Current Assets249.87M353.46M133.54M161.07M418.46M
Property, Plant & Equipment (Net)53.35M52M45.36M35.77M30.27M
Goodwill00000
Intangible Assets00000
Long-term Investments68.37M00014.35M
Tax Assets00000
Other Non-current Assets3.23M201.94M203.1M157.32M22.5M
Total Non-current Assets124.95M253.94M248.46M193.09M67.11M
Total Assets374.82M607.4M382M354.16M485.57M
Account Payables3.1M1.55M1.52M2.24M2.57M
Short-term Debt17.44M00010.95M
Tax Payables0005.85M0
Deferred Revenue98K24K000
Other Current Liabilities25.15M(24K)12.88M06.91M
Total Current Liabilities58.59M28.72M24.77M32.09M38.3M
Long-term Debt599.39M00032.8M
Deferred Tax Liabilities240K00085.68M
Deferred Revenue (Non-current)310K192K000
Other Non-current Liabilities2.18M91.29M99M107.42M313K
Total Non-current Liabilities654.81M136.89M144.24M146.53M150.55M
Total Liabilities713.39M165.6M169M178.62M188.85M
Common Stock1K1K001K
Retained Earnings(1.73B)(853.91M)(909.1M)(965.52M)(859.63M)
Accumulated OCI(0)(15K)(65K)7K61K
Other Stockholders Equity00(0)(0)0
Minority Interest00000
Total Equity(338.57M)441.8M213M175.55M296.72M
Total Debt669.52M52.16M49.16M49.82M75.5M
Net Debt579.56M(246.01M)9.61M12.02M(92.31M)

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.